Amneal Pharmaceuticals (AMRX) Common Equity: 2017-2025
Historic Common Equity for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to -$110.0 million.
- Amneal Pharmaceuticals' Common Equity fell 17.51% to -$110.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$110.0 million, marking a year-over-year decrease of 17.51%. This contributed to the annual value of -$109.5 million for FY2024, which is 647.26% down from last year.
- Per Amneal Pharmaceuticals' latest filing, its Common Equity stood at -$110.0 million for Q3 2025, which was up 2.29% from -$112.5 million recorded in Q2 2025.
- In the past 5 years, Amneal Pharmaceuticals' Common Equity ranged from a high of $407.4 million in Q1 2022 and a low of -$132.0 million during Q1 2025.
- For the 3-year period, Amneal Pharmaceuticals' Common Equity averaged around -$19.9 million, with its median value being -$63.6 million (2024).
- In the last 5 years, Amneal Pharmaceuticals' Common Equity grew by 11.10% in 2022 and then crashed by 647.26% in 2024.
- Quarterly analysis of 5 years shows Amneal Pharmaceuticals' Common Equity stood at $367.0 million in 2021, then slumped by 49.87% to $184.0 million in 2022, then plummeted by 89.12% to $20.0 million in 2023, then crashed by 647.26% to -$109.5 million in 2024, then fell by 17.51% to -$110.0 million in 2025.
- Its Common Equity stands at -$110.0 million for Q3 2025, versus -$112.5 million for Q2 2025 and -$132.0 million for Q1 2025.